Margaret Macro

Caen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 105 publications

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Journal: Leukemia

Published: February 18, 2026

A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.

A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.

Journal: British journal of haematology

Published: January 28, 2026

Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' reply.

Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' reply.

Journal: The Lancet. Oncology

Published: January 12, 2026

Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.

Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.

Journal: Clinical hematology international

Published: December 04, 2025

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Journal: JMIR formative research

Published: August 07, 2025

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Journal: Blood cancer journal

Published: July 07, 2025

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 03, 2025

Multiple myeloma of the bones

Multiple myeloma of the bones

Journal: La Revue du praticien

Published: June 06, 2025

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.

Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.

Journal: The New England journal of medicine

Published: June 03, 2025

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

Journal: Blood

Published: May 15, 2025

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.

Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 18, 2025

Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.

Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 09, 2025

Showing 1-12 of 105

Last Updated: 09/26/2026